Eli Lilly's EloraTZP Shows Greater Weight and A1C Reduction in Phase 2b Trial
Eli Lilly's experimental drug EloraTZP, a combination of eloralintide and tirzepatide, demonstrated superior weight loss and A1C reduction compared to tirzepatide 15 mg in a 48-week Phase 2b study. Participants taking EloraTZP lost significantly more weight and saw greater improvements in their blood sugar levels.
Indianapolis, IN – A new experimental drug combination, EloraTZP, developed by Eli Lilly, yielded greater weight loss and better blood sugar control than tirzepatide 15 mg alone in adults with obesity and type 2 diabetes. Researchers presented these findings from a 48-week Phase 2b study.
Participants receiving EloraTZP experienced an average weight loss of up to 54.1 pounds, representing a 23.3% reduction from their initial weight. In comparison, individuals on tirzepatide 15 mg lost an average of 34.4 pounds, a 14.8% reduction.
The study also showed EloraTZP's effectiveness in improving glycemic control. Participants using EloraTZP reduced their A1C levels by up to an average of 2.9%. Those in the tirzepatide 15 mg group saw an average A1C reduction of 2.4%.
Related Topics
Article Ratings
How do you feel about this story?
National Desk
Sign in to follow this author from their profile.
Discussion (0)
Join the Conversation
Join the conversation
Sign in to share your thoughts, reply to readers, and like comments.
No comments yet. Be the first to comment!